SCHEMBL9607868

SCHEMBL9607868

C[C@@H]1OC(O[C@H]2C[C@](O)(C(=O)CO)Cc3c(O)c4c(c(O)c32)C(=O)c2c(CO)cccc2C4=O)C[C@H](N)[C@H]1O

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.84
THRB P10828 10/20 0.84
KMT2A Q03164 10/20 0.84
BLM P54132 9/20 0.84
RECQL P46063 8/20 0.84
HIF1A Q16665 7/20 0.84
SMN1; SMN2 Q16637 7/20 0.84
MAPT P10636 7/20 0.84
BRCA1 P38398 7/20 0.84
TDP1 Q9NUW8 6/20 0.84
MAPK1 P28482 6/20 0.84
TOP2A P11388 5/20 0.84
HTT P42858 5/20 0.84
STAT6 P42226 5/20 0.84
CHRM1 P11229 4/20 0.84
KDM4E B2RXH2 4/20 0.84
ALDH1A1 P00352 4/20 0.84
TBXA2R P21731 3/20 0.84
ABCB1 P08183 3/20 0.84
NR3C1 P04150 3/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10119585 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL9889374 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL10061864 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL9942593 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL10061915 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL15890537 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL17752025 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL9607869 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL94868 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL
SCHEMBL9889375 1.00 MEN1 (0.84) MEN1THRBKMT2ABLMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828925-B2 Etoposide and doxorubicin conjugates for drug delivery ANGIOCHEM INC. (CA) 2014-09-09 US disclosed
US-20120135914-A1 ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY ANGIOCHEM INC. (CA) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135914-A1 ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY GLS, AQP4, ABCB1 MEN1 582/4885THRB 4818/4885KMT2A 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.